



Spanish Securities Market Commission  
For the attention of: The Manager, Markets Division  
C/ Edison núm. 4  
28006 Madrid

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 228 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following **REGULATORY ANNOUNCEMENT**:

"Find attached press release that Pharma Mar, S.A. will distribute to the media where Pharma Mar announces that the phase II trial of lurbinectedin as a single agent, which is conducted by Pharma Mar in recurrent small cell lung cancer, has reached the recruitment of 100 patients expected in the trial."

In Colmenar Viejo (Madrid), on 14 November 2018

## PharmaMar announces the meeting of its patient recruitment target in the phase II study with lurbinectedin as a single agent in small-cell lung cancer

- The forecasted goal of recruiting 100 patients in the phase II trial with lurbinectedin as a single agent in small-cell lung cancer (SCLC) has been achieved
- The study's primary endpoint is overall response rate. Other secondary endpoints such as the duration of response, progression free survival, overall survival, along with the safety profile will also be evaluated

Madrid, 14<sup>th</sup> of November 2018. PharmaMar (MSE:PHM) has announced today that the recruitment goal of 100 patients in the phase II trial with lurbinectedin as a single agent in recurrent SCLC has been reached.

The study's primary endpoint is overall response rate (ORR), while also evaluating secondary endpoints such as the duration of response (DR), progression free survival (PFS), overall survival (OS), along with the safety profile.

This multicenter, phase II "basket", clinical trial, involving 38 centers from nine different countries, will assess the safety and efficacy of lurbinectedin in patients with recurrent SCLC, this meaning, those patients who have received a prior chemotherapy treatment.

In June, [PharmaMar presented data](#) on 61 patients from this cohort with recurrent small-cell lung cancer at the American Society of Clinical Oncology (ASCO) Congress in the abstract entitled "[Efficacy and safety of lurbinectedin \(PM1183, Zepsyre®\) in small-cell lung cancer \(SCLC\): results from a phase 2 study](#)". An ORR of 39.3% was seen in these patients. The median DR was 6.2 months and the median OS, 11.8 months.

*"We have observed that lurbinectedin as a single agent is active in patients with recurrent small-cell lung cancer and that, according to the data observed so far, there*



*is a high percentage of responses,"* explains **Dr. Ali Zeiter**, Director of Clinical Development at the Oncology Business Unit at PharmaMar.

#### **Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

#### **About PharmaMar**

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several ty-pes of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

#### **About lurbinectedin**

Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

#### **Media Contact:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34 609493127

Miguel Martínez-Cava – Digital Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464

Phone: +34 918466000



#### **Investor Relations:**

Phone: +34 914444500

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)